Hadassah

Pro-Tumor White Blood Cells Discovered at Hadassah

Tuesday, Feb 3 2015

Researchers at the Hadassah Medical Organization and Hebrew University have found that the most common form of white blood cells, called neutrophils, contain at least three distinct subtypes. Some fight the development of cancer, while others provide a hospitable environment for their growth.

The research findings could lead to new cancer-fighting therapies that seek to boost the anti-tumor neutrophils while limiting the proliferation of pro-tumor neutrophils.

In the last decade new approaches to cancer have involved activating the patient’s immune system against cancer cells, while not harming nearby healthy cells. Recently, however, researchers have discovered that there are healthy cells which surround the tumor that play an important role in enhancing cancer development. Thus, while neutrophils, which comprise between 50-70 percent of all white blood cells, are traditionally associated with fighting infections, accumulating data suggest they also play an important role in tumor biology. The Hadassah-Hebrew University scientists, working with mouse tumors and human blood samples, found that in early stages of the disease, tumor-limiting neutrophils prevail, but as cancer progresses, the tumor-promoting neutrophil subpopulation becomes dominant. As the authors explain:

“We identified a heterogeneous subset of low-density neutrophils (LDNs) that appear transiently in self-resolving inflammation, but accumulate continuously with cancer progression. LDNs display impaired neutrophil function and immunosuppressive properties, characteristics that are in stark contrast to those of mature, high-density neutrophils (HDNs). Proper understanding of the effect of tumors on neutrophils, as well as the way these cells support or fight cancer, could help us develop strategies to direct the immune system against the tumor, and potentially improve cancer treatment in general and immunotherapy in particular."

The research study, led by Dr. Zvi Fridlender, at the Hadassah-Hebrew University Medical Center’s Institute of Pulmonary Medicine, and Dr. Zvika Granot, at the Hebrew University’s Institute for Medical Research Israel-Canada (IMRIC) in the Faculty of Medicine, is highlighted in "Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer" in the January 22, 2015 on-line issue of Cell Reports.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Thyroid Cancer Diagnosis Enhanced at Hadassah Using Advanced Gene Sequencing

Hadassah Medical Organization researchers, using next generation sequencing (NGS), have identified a highly accurate RNA panel that distinguishes thyroid cancer from benign nodules.

READ MORE ›
alt_text

Thursday, Aug 2 2018

Two Hadassah Ophthalmology Articles Are Among Top 100 Most Cited in Four Decades

Two articles by Hadassah Medical Organization ophthalmologists are among the 100 most cited ophthalmology articles from 1975-2017. One is ranked 11th.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More